Table 3.
Analysis of signalling lymphocyte activation molecule receptors on CD4+, CD8+ and double negative T cells
| Frequency of positive cells | Intensity of expression | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLAM | Cell population | % | P-values | MFI | P-values | ||||||||
| A | I | HD | A vs I | A vs HD | I vs HD | A | I | HD | A vs I | A vs HD | I vs HD | ||
| (n = 19) | (n = 11) | (n = 20) | (n = 19) | (n = 11) | (n = 20) | ||||||||
| SLAMF2 (CD48) | CD4+ | 73.38 (32.44) | 65.31 (23.55) | 82.89 (20.15) | 0.7185 | 0.5290 | 0.2191 | 2919 (783.7) | 3091 (635.0) | 2421 (348.1) | 0.7579 | 0.0490* | 0.0220* |
| CD8+ | 52.02 (28.78) | 43.58 (28.60) | 49.64 (24.57) | 0.7124 | 0.9626 | 0.8390 | 2381 (594.2) | 2718 (383.3) | 2094 (376.8) | 0.1609 | 0.1660 | 0.0031* | |
| DN | 93.03 (10.82) | 93.66 (6.30) | 44.95 (25.17) | 0.9954 | <0.0001* | <0.0001* | 1709 (679.3) | 1609 (600.1) | 2249 (351.6) | 0.8925 | 0.0148* | 0.0148* | |
| SLAMF3 (CD229) | CD4+ | 91.71 (15.20) | 78.68 (14.18) | 88.32 (18.27) | 0.0991 | 0.7940 | 0.2668 | 451.8 (80.46) | 337.1 (39.86) | 448.3 (111.5) | 0.0037* | 0.9915 | 0.0046* |
| CD8+ | 81.14 (20.27) | 3.93 (3.45) | 70.85 (37.22) | <0.0001* | 0.4607 | <0.0001* | 556.8 (198.7) | 435.6 (79.88) | 366.1 (64.60) | 0.3911 | 0.0241* | 0.0018* | |
| DN | 73.66 (23.15) | 59.27 (12.86) | 76.62 (24.77) | 0.2059 | 0.9123 | 0.1094 | 495.8 (153.4) | 544.1 (51.22) | 630.1 (122.1) | 0.5684 | 0.0058* | 0.1822 | |
| SLAMF4 (CD244) | CD4+ | 1.97 (2.66) | 1.39 (1.90) | 0.96 (1.57) | 0.7486 | 0.3073 | 0.8555 | 206.6 (48.66) | 209.9 (57.56) | 198.2 (21.63) | 0.9766 | 0.8099 | 0.7422 |
| CD8+ | 37.08 (23.10) | 22.14 (20.49) | 41.38 (18.32) | 0.1489 | 0.7951 | 0.0442* | 244.8 (43.43) | 208.6 (9.97) | 245.2 (33.75) | 0.0223* | 0.9994 | 0.0195* | |
| DN | 25.04 (14.18) | 20.53 (22.0) | 55.67 (19.66) | 0.5410 | <0.0001* | <0.0001* | 285.9 (77.06) | 226.5 (21.38) | 265.2 (44.47) | 0.0249* | 0.2729 | 0.1578 | |
| SLAMF5 (CD84) | CD4+ | 56.41 (9.49) | 48.39 (16.88) | 51.83 (13.56) | 0.2708 | 0.5271 | 0.7746 | 366 (99.88) | 336.3 (88.91) | 399.5 (91.58) | 0.7058 | 0.5240 | 0.2056 |
| CD8+ | 54.71 (38.80) | 6.49 (9.17) | 37.70 (33.53) | 0.0015* | 0.1148 | 0.0341* | 472.2 (202.6) | 494.9 (382.1) | 466.8 (135.1) | 0.9657 | 0.9971 | 0.9462 | |
| DN T | 76.06 (14.17) | 72.27 (14.19) | 65.89 (12.33) | 0.7577 | 0.0722 | 0.4595 | 432.3 (130.7) | 345.9 (62.67) | 432.5 (143.1) | 0.1986 | 1 | 0.1974 | |
| SLAMF6 (CD352) | CD4+ | 52.34 (23.27) | 29.26 (22.39) | 36.59 (26.70) | 0.0459* | 0.1356 | 0.7117 | 1617 (429.4) | 1324 (205.4) | 1545 (559.4) | 0.2193 | 0.8819 | 0.4059 |
| CD8+ | 55.55 (22.05) | 31.62 (31.97) | 45.05 (28.63) | 0.0660 | 0.4744 | 0.4003 | 1976 (516.6) | 1600 (211.7) | 1950 (695.7) | 0.1862 | 0.9885 | 0.2251 | |
| DN | 65.96 (19.14) | 47.37 (31.08) | 56.69 (39.71) | 0.2740 | 0.6476 | 0.7163 | 1943 (476.1) | 1634 (217.6) | 1970 (714.8) | 0.3074 | 0.9876 | 0.2494 | |
| SLAMF7 (CD319) | CD4+ | 13.35 (30.69) | 2.55 (4.54) | 12.72 (23.10) | 0.5661 | 0.9353 | 0.5661 | 628.5 (426.9) | 379.5 (78.29) | 410.9 (144.4) | 0.0588 | 0.0588 | 0.7677 |
| CD8+ | 39.22 (30.28) | 13.13 (12.81) | 43.72 (15.67) | 0.0084* | 0.7999 | 0.0016* | 559.4 (469.6) | 327.5 (59.54) | 362 (47.23) | 0.1038 | 0.1007 | 0.9477 | |
| DN | 34.61 (28.25) | 27.17 (21.05) | 63.94 (13.44) | 0.6488 | 0.0006* | 0.0002* | 584.8 (397.9) | 371.6 (75.72) | 399.3 (67.50) | 0.0847 | 0.0837 | 0.9576 | |
Frequency of positive cells and intensity of expression. Data are from healthy donors and active and inactive LN patients. Results are expressed as the mean (s.e.m.). The P-values were considered statistically significant when P < 0.05 according to one-way analysis of variance with Tukey’s multiple comparison test.
*Significant P-values. A: SLE patients with active LN; HD: healthy donors; I: SLE patients with inactive LN; SLAM: signalling lymphocyte activation molecule.